Semaglutide linked to 26% lower 5-year predicted dementia risk

A study published in the journal Alzheimer's & Dementia found that semaglutide use is associated with a 26% lower five-year predicted risk of dementia. The finding adds to a growing body of evidence for broader therapeutic uses of GLP-1 receptor agonists beyond diabetes and weight loss.